In solid first quarter, Spinraza revenues support Biogen's move into neuropsychiatry

24 April 2018

East Coast, USA-based Biogen (Nasdaq: BIIB) has reported total revenues of $3.1 billion for the first three months of 2018, an 11% increase from the first quarter of last year, just shy of most analysts’ expectations.

Following generally accepted accounting principles, the company booked net income of $1.2 billion, a more than 50% increase from 2018, with earnings per share up 60% at $5.54.

Revenue growth was principally driven by spinal muscular atrophy (SMA) drug Spinraza (nusinersen), which added a third of a billion dollars in global takings, as well as biosimilars, which contributed $128 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK